Embecta Corporation (EMBC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 results. Read more here.

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Embecta reports fourth quarter earnings beating estimates, discontinues insulin patch program, and announces restructuring ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Good day, and welcome to the Embecta fourth quarter of fiscal year 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Debt Pay Down (Q4 2024): Additional $25 million of Term Loan B debt paid down. Embecta Corp (NASDAQ:EMBC) strengthened its core business by securing exclusive and dual-preferred contracts with key ...

The Board of Directors of Embecta Corp. ("embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each ...